Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes
2011

How New Diabetes Drugs Spread in Taiwanese Hospitals

Sample size: 580 publication 10 minutes Evidence: high

Author Information

Author(s): Wen Yu-Wen, Huang Weng-Foung, Lee Yue-Chune, Kuo Ken N, Tsai Chia-Rung, Tsai Yi-Wen

Primary Institution: Chang Gung University

Hypothesis

The study investigates how thiazolidinediones (TZDs) diffuse in the healthcare market in Taiwan.

Conclusion

Medical centers began to prescribe TZDs earlier and at a faster pace compared to other hospitals.

Supporting Evidence

  • Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of TZDs.
  • Adoption of TZDs was slower in district hospitals than in medical centers.
  • Non-profit hospitals adopted TZDs faster than public hospitals.

Takeaway

This study looks at how quickly hospitals in Taiwan started using a new diabetes drug and how much they used it over time.

Methodology

The study analyzed monthly prescription data for TZDs from 580 hospitals in Taiwan using Cox proportional hazards model and quantile regressions.

Potential Biases

Potential biases may arise from the exclusion of clinics and hospitals with low prescription volumes.

Limitations

The study lacks information on the margin between reimbursed price and pharmaceutical procurement cost, which may affect the findings.

Participant Demographics

The study included 580 hospitals treating patients with Type 2 diabetes in Taiwan, categorized by accreditation level and ownership type.

Statistical Information

P-Value

0.0000

Confidence Interval

95% CI = 0.01 to 0.04

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1472-6963-11-21

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication